Tel Aviv, Israel, March 30, 2026 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW) today announced that effective as of March 26, 2026, it has officially changed its corporate name to Nexera Technologies Ltd. (“Nexera”), reflecting the Company’s strategic shift toward advanced technologies and homeland security solutions. It is expected that effective March 31, 2026, the Company’s ordinary shares will begin trading on the Nasdaq Capital Market under the new ticker symbol “NEXR”, replacing the previous ticker “JFBR.” The Company’s warrants are expected to trade under the symbol “NEXRW,” replacing the previous ticker “JFBRW.” The corporate name change follows the Company’s previously announced rebranding initiative and strategic repositioning to focus on homeland security technologies,...

– Full enrollment of BLA-enabling trial complete, per prior guidance –– Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded Chief Medical Officer, formerly of Merck and Johnson & Johnson for BLA submission – LOS ANGELES, CA, March 30, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that NEXICART-2 enrollment is complete, meeting Company guidance, with topline results expected in Q3 2026, followed by BLA submission and planned commercial launch. “In AL Amyloidosis, the immune system produces toxic light chains that clog up the heart, kidney and liver, causing organ failure and death. In our trials, we have seen that one-and-done NXC-201 eliminates...

Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations ARLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) — KALA BIO, Inc. (NASDAQ: KALA) (“Kala” or the “Company”) today announced the initial commercial deployment of the Bionic Intelligence Research Agent (BIRA), the Company’s first purpose-built agentic AI solution delivered through its Researgency.ai platform (under exclusive worldwide license with Younet). This milestone marks Kala’s transformation into an operational AI infrastructure partner for the global biotechnology industry. The launch follows the Company’s March 11 announcement that its first AI agent would ship within 14 days, a commitment Kala has met on schedule, demonstrating...

IRVINE, CA, March 30, 2026 (GLOBE NEWSWIRE) — Clean Energy Technologies, Inc. (Nasdaq: CETY) (“CETY” or the “Company”), a clean energy technology and solutions provider focused on converting waste and heat into power and fuels, today announced the execution of a non-binding Letter of Intent (“LOI”) with Hoppy Power Ltd. (“Hoppy Power”) to evaluate and advance the deployment of CETY’s proprietary High Temperature Ablative Pyrolysis (HTAP™) technology for waste-to-energy applications. This initiative represents a meaningful step toward near-term deployment and initial commercialization, with defined milestones in 2026 expected to include engineering validation, permitting progression, and advancement toward definitive agreements. The Company anticipates providing further updates as these milestones are achieved, supporting...

Shenzhen, China, March 30, 2026 (GLOBE NEWSWIRE) — Baiya International Group Inc. (“BIYA” or the “Company”) (Nasdaq: BIYA), a human resource (“HR”) technology company utilizing its cloud-based internet platform to provide one-stop crowdsourcing recruitment and SaaS-enabled HR solutions, today announced the official launch of its Cryptocurrency Ark Plan (the “Plan”), alongside the introduction of a global voting mechanism to determine the direction of its next phase of digital asset allocation. This initiative marks an evolution in the Company’s asset allocation strategy, establishing a more structured framework under the Plan that integrates market-driven decision-making with a disciplined allocation approach. Global Vote Begins: Letting the Market Decide the Ark’s First Destination The Company plans to launch a one-week global...

COCONUT CREEK, Fla., March 30, 2026 (GLOBE NEWSWIRE) — Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”), the leading lessor of commercial aircraft engines and a global provider of aviation services, today announced that it has amended and extended its existing revolving credit facility, increasing total commitments from $1.0 billion to $1.75 billion and extending the maturity to April of 2031. The amended facility was oversubscribed, with approximately $1.0 billion in excess lender commitments, reflecting strong support from the Company’s lenders/partners. “We are very pleased to complete the expansion and extension of our revolving credit facility, reflecting the strength and confidence the markets have in our platform,” said Scott B. Flaherty, EVP & Chief Financial Officer of Willis Lease Finance...

Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data  In vitro analysis of the SeaStar Medical SCD indicates modulation of the immune response, shifting monocytes towards an anti-inflammatory, reparative phenotype SeaStar Medical hosts an industry symposium and panel discussion focused on innovation in the treatment of pediatric AKI, supporting its emerging leadership in this community DENVER, March 30, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today the presentations of new SAVE Registry data and investigator led research on the mechanism of action...

Company Confirms Sufficient Liquidity to Execute FY2026 Growth Plan; Related Share Cancellation to Reduce Outstanding Shares to 3,274,828 Singapore, March 30, 2026 (GLOBE NEWSWIRE) — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group” or the “Company”), a global leader in on-demand workforce solutions and integrated facilities management (IFM), today announced that it has instructed its sales agents, Spartan Capital Securities, LLC and Wilson-Davis & Co., Inc., to pause the Company’s At-The-Market (“ATM”) equity offering program, effective immediately. In connection with the pause, the Company has directed the return and cancellation of 1,004,107 shares of common stock that were allocated to the sales agents but were not offered or sold into the market. Upon completion of the cancellation process, total shares...

LAS VEGAS, NV, March 30, 2026 (GLOBE NEWSWIRE) — Eva Live Inc. (NASDAQ: GOAI), a high-growth AI-driven digital advertising and marketing technology company, today announced that it has engaged Anderson Kill P.C. to actively support the Company’s execution of a strategic initiative to align GOAI with Nasdaq’s newly announced tokenization framework. The Anderson Kill P.C. team is led by Louis L. Nock, a Shareholder of the firm and former New York State Supreme Court Justice who concentrates on the emerging legal, regulatory, and corporate aspects of Digital Assets and Blockchain Technology. Nasdaq’s introduction of tokenized securities trading marks a transformative shift in global capital markets, enabling blockchain-based settlement, expanded investor access, and the potential for extended or 24/7 trading environments. As a Nasdaq-listed...

Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the second patient in the second cohort (fifth patient overall) in its Phase 1 CER-1236 clinical trial in hematologic malignancies, including acute myeloid leukemia (AML), with planned expansion into myelodysplastic syndromes (MDS) and myelofibrosis (MF).   With more than seven days of follow-up completed after the second patient’s infusion, protocol-defined monitoring of safety, pharmacokinetic, pharmacodynamic, and clinical...